1. Company overview: The Dharamsi Morarji Chemical Company Limited (DMCC) is a fully integrated speciality chemicals player in sulphur, boron and ethanol chemistry.
They have over 100 years of experience in sulphur chemistry and have also diversified their operations across other downstream products. Their products find usage in a wide range of industries such as pharmaceuticals, detergents, dyes, fertilisers, pigments and cosmetics.
2. History: DMCC was established in 1919 as a producer of sulphuric acid and fertilizers. At the time, they were largely focused on the fertiliser business, which at that point, contributed to ~75% of the revenues.
From the year 2000 onwards, the fertiliser business began incurring losses. In 2009, the company decided to discontinue the fertilizer business and focus on manufacturing bulk sulphuric acid and its downstream chemicals.
They merged the business of Borax Morarji(Promoter company) with the sulphur business in 2016. 3. Business segments: The company currently operates in 3 main segments:
i)Bulk Chemicals: DMCC manufactures sulphuric acid and its by-products
which is then sold within a limited radius from the manufacturing site. Almost 50% of the bulk chemicals that is manufactured is sold in the market while the remaining 50% is used for captive consumption.
ii) Specialty Chemicals: Under this segment, the company makes various downstream chemicals from sulphur through reactions with phenol, benzene and methanol. They have backward integration for this segment. 65-70% of speciality chemicals are exported
iii)Boron Chemistry: This segment produces various commodity and downstream products of boron. However, in recent years, this business has been crippled due to unfavourable government policy around the import of boron.
4. Key products β Sulphuric acid, benzene sulfonyl chloride, sodium vinyl sulfonate and diethyl sulphate.
5.Revenue split by segment: Specialty chemicals β 65%, Bulk Chemicals β 35%
Revenue split by geography: Europe β 54.91%, North America β 20.65%, Asia β 23.75%, ROW β 0.69%
6.Manufacturing Facilities :The company has 2 manufacturing plants in Roha and Dahej.
Roha β This plant is produces products in sulphur chemistry.They have 10 dedicated and 3 MPPs at this site.Apart from that, they also have 25% more land available for future expansion
Dahej β They acquired this plant through the merger with Borax Morarji in 2016. Boron and sulphur products are manufactured at this site. They have an additional 50% vacant land available at this site for future expansion
7. R&D expenditure: The company spent 2.1 Cr on R&D in 2021 which is about 1% of revenue. 8. Capex: The company is spending βΉ100Cr on expanding its capacities. A major chunk of this(about βΉ50Cr) is being spent on setting up a new bulk sulphuric acid plant at the Dahej facility
which is expected to be completed by Q2 FY22. The remainder is being spent on setting up MPPs to manufacture various specialty chemicals and intermediates.
10. Future Outlook: The company is expected to complete all capacity expansion by March 2022.The new bulk chemicals facility is expected to come on stream in Q3,at which point the company will see a contraction in margins due to higher contribution from the bulk chemicals segment
Margins will return back to current levels after the capacity expansion is done on the specialty segments side. Management has indicated that the new bulk chemicals plant will be more than enough to take care of their feedstock needs for the foreseeable future and all further
capex for the coming years will be made on the specialty chemicals side. So there seems to be scope for margin expansion.
11. Risks :
i) A significant part of the revenues come from the bulk commodities segment which is very dependent on the price of crude and sulphur.
ii)The Roha plant was set up in 1978. Since it is an old plant, the chances of unforeseen breakdown is high. Sulphur plants also need to be shut down for 30 days every 18 months for maintenance. Both these risks however are mitigated by setting up the plant in Dahej.
β’ β’ β’
Missing some Tweet in this thread? You can try to
force a refresh
#neogenchemicals notes with B&K securities :
π§ͺβοΈ
Like and retweet !!
1. Products and contracts
During the lockdown the company received two long term contracts
i)Innovator pharma customer who is already purchasing some molecules from neogen
ii)International agro innovator with whom neogen is working for complex 6-7 stage molecules
After the VAM machines were introduced in India, Neogen was the first company to manufacture Lithium bromide required in VAM machines
Current revenue mix is 50% bromine 30% advance intermediates(10% CSM) and 20% lithium which will change to 40% bromine 40% advance intermediates (20% CSM) and 20% lithium.
Sequent Scientific just published their Annual Report for FY2021. Here are some of the key highlights. 1. 65% of revenue came from regulated markets whereas 35% came from less regulated markets.
Of this, 66% revenue was from formulations and 34% was from API. 2. Figures: βΉ905Cr from Formulations and βΉ456Cr from API
The business generated over βΉ150Cr in cash from operations alone.
CFO/EBITDA for the year stood at 73.27%
3. Revenues for the formulation business were as follows : 46% Europe(3.8% yoy growth), 18% Turkey(37.3% yoy growth), 17% LATAM(78.5% yoy growth), 10% Emerging Markets(31.3% yoy decline), 9% India(98.4% yoy growth)
#valiantorganics Update : 1. OA capacity expanded to 4800 MT 2. ONA (Raw material for OA) capacity increased to 7200 MT. It will increase the margins. (New Product) 3. #PAP#paraaminphenol Production started. 200 MT in Q1 and expected to be 2300 MT in FY22. Total capacity 9000MT
4. Increased the stake in bharat chemicals from dhanvallabh venture LLP ( from 40 to 50%) 5. #bharatchemicals capacity of #paracetamol increased to 9000 MT 6. Raw material price increased in Q1, which will be passed on in Q2. #OA,#ONA,#PA,#PNA,#PAP will started contributing
7. New capex for #apis (chemicals for APIs). Mostly for apis manufactured by #aartiindustries and #aartidrugs
Intermediates will be manufactured for following APIs : 1. Ranolazine 2. Benazeprill 3. Elagolix 4. Pranlucast 5. Moxifloxacin 6. Ramipril 7. Montelukast 8. Quinapril
An analysis of #Sequent - Indiaβs largest Animal Health Company
Like and retweet for more learnings πΆπ
A thread!𧡠1. Points covered : 2. Promoters and management 3. Company overview 4. Why is it different from human pharma 5. Opportunity size 6. Stability of business
7. FMCG like business 8. Barriers to entry 9. Manufacturing facilities 10. Summary of financials 11. Major acquisitions 12. Capex Details 13. Reduced Debt 14. Future Growth prospects 15. Valuation
Promoters and management
Carlyle Group - Private equity firm Carlyle Group acquired a majority stake in Sequent in 2020 and are the new promoters of the company. They have a lot of experience investing in the healthcare sector both in India and globally.
Here are some downstream derivatives for #phenol #Deepaknitrite will be doing 700 Cr capex for the products which are used in paints & coatings , lifesciences.
Check the following list & comment what can be downstream derivatives of #phenol ?
Like and retweet for more learningsπ§ͺ